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Abstract
Background: MCPIP is a novel CCCH zinc finger protein described as an RNase engaged in the regulation of
immune responses. The regulation of expression of the gene coding for MCPIP - ZC3H12A is poorly explored.
Results: Here we report that the proinflammatory cytokine IL-1b rapidly induces the synthesis of MCPIP in primary
monocyte-derived macrophages and HepG2 cells. This up-regulation takes place through the MAP kinase pathway
and following activation of the transcription factor Elk-1. Using a ZC3H12A reporter construct we have shown that
a ZC3H12A promoter region, stretching from -76 to +60, mediates activation by IL-1b. This region contains binding
sites for Elk-1 and its partner SRF. Chromatin immunoprecipitation analysis confirms in vivo binding of both
transcription factors to this region of the ZC3H12A promoter.
Conclusions: We conclude that the transcription factor Elk-1 plays an important role in the activation of ZC3H12A
expression in response to IL-1b stimulation.
Background
MCPIP has RNase activity that prevents some immune
disorders by direct control of the stability of a set of
inflammatory transcripts [1,2]. MCPIP-deficient mice
die within 12 weeks with the symptoms of severe
inflammatory changes. Among transcripts destabilized
by MCPIP are the mRNAs for IL-6, IL-12p40, calcitonin
receptorand and IL-1b [1,2]. MCPIP contains a PIN
domain, responsible for it’s enzymatic activity and
CCCH zinc finger domain, partially also engaged in the
control of transcripts decay [1,2]. MCPIP is induced in
human peripherial blood monocytes by monocyte che-
moattractant protein (MCP-1) and this phenomenon
resulted in the name of this protein as a MCP-1 induci-
ble protein (MCPIP) [3]. The significance of MCPIP in
the course of inflammation is manifested also in the
development of cardiovascular diseases. Elevated level of
MCPIP is associated with ischemic heart disease [3].
Recently it was found that Toll-like receptors are
involved in the activation of mice Zc3h12a (gene
encoding MCPIP). The activation of Zc3h12a was
revealed by microarray analysis of RNA from macro-
phages of wild-type, Myd88-/- and Trif-/-mice stimulated
with liposacharide (LPS) [1]. We have observed that the
level of transcript for MCPIP is rapidly induced by IL-
1b in monocytes, fibroblasts and hepatoma HepG2 cells
[2]. IL-1b is a proinflammatory cytokine produced very
early in response to multiple stress. It exerts pleiotropic
effects on different cell types. Binding of IL-1b to IL-1RI
leads to activation of the kinase TAK1, which finally
results in the activation of NFB but also activation of
MAP kinases (namely ERK, p38 and JNK) [4].
Among different transcription factors phosphorylated
by MAPKs are the ternary complex factors (TCF), the
subfamily of ETS-domain transcription factors [5]. The
TCF subfamily include Elk-1, SAP-1 and SAP2/ERP/
Net. These proteins form ternary complexes on target
promoters together with MADS-box protein, serum
response factor (SRF). All TCFs share the ETS-domain
which is engaged in DNA-binding, the B-box responsi-
ble for association with SRF, the transcriptional-activa-
tion domain that can be phosphorylated on multiple
serine and threonine residues, and the docking domain
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which interacts with MAPKs [5]. Elk-1 and SAP-1 are
thought to act as activators whereas SAP-2 is thought to
play mainly a repressive role. A series of events initiated
by phosphorylation of transcription factors from the
TCF subfamily are still under investigation. Phosphory-
lation induces conformational changes and influences
the interaction of transcription factors with other co-
activators/co-repressors. The details of this process are
quite well understood for Elk-1. Phosphorylation leads
to its de-repression through the reversing of its sumoy-
lation and subsequent dissociation of HDAC-2 [6].
Phosphorylated Elk-1 recruits Mediator through the
coactivator Sur-2/Med23 and interacts with p300/CBP
which causes the enhancement of acetylation of histones
of target promoters [7,8]. Recently it was also shown
that histone acetylation initiated by phoshorylation of
Elk-1 on the c-fos promoter leads to association of a
second transcription factor, NFI, which in turn leads to
the recruitment of the basal machinery and subsequent
promoter activation [9].
The mechanisms controlling the regulation of MCPIP
expression are largely unknown. Here, we have shown
that IL-1b regulates expression of the gene coding for
MCPIP - ZC3H12A through the activation of the ERK
pathway. We have found that Elk-1 and SRF are tran-
scription factors engaged in this regulation.
Results
IL-1b regulates the expression of ZC3H12A via activation
of the NFkB and ERK pathways
Our data indicate that MCPIP mRNA level is upregu-
lated by proinflammatory cytokine IL-1b and that this
regulation takes place through the activation of NFB
[10]. To test whether other pathways are engaged in the
regulation of ZC3H12A expression we have examined
the stimulation of MCPIP mRNA synthesis in a HepG2
cell line with blocked NFB activation (mIB cells). In
this cell line NFB is not activated by IL-1b at all
whereas in both wild-type HepG2 cells and MOCK cells
there is a rapid activation of NFB (Additional file 1,
Fig. S1). In mIB cells IL-1b still increases the MCPIP
mRNA level although the fold of this stimulation is
much weaker than in the control (MOCK cells). Phorbol
12-myristate 13-acetate (PMA) increases the effect of IL-
1b both in MOCK cells and in mIB cells. (Fig. 1A and
1B, lane 2 and 4). These results suggest that IL-1b regu-
lates the expression of ZC3H12A not only via activation
of NFB. In contrast to IL-1b, PMA stimulates the
synthesis of MCPIP transcript in both cell lines (MOCK
cells and mIB cells) in a comparable manner (Fig. 1A
and 1B, lane 3). We speculated that the possible path-
way engaged in the observed stimulation of ZC3H12A
could be the MAPK pathway. IL-1b can activate the
p38, JNK and ERK kinases which phosphorylate
transcription factors [11,12]. We tested the involvement
of one of them, namely ERK. To examine the role of
ERK in the activation of ZC3H12A expression we have
used U0126 - a known inhibitor of MEK1/2. U0126
inhibited the activation of ZC3H12A by IL-1b and PMA
in both MOCK and mIB cells (Fig.1A and 1B). These
observations suggest that besides NFB activation path-
way, the ERK pathway is responsible for rapid activation
of ZC3H12A expression. ERK is activated by IL-1b in
HepG2 cells and its phosphorylation is blocked when
the ERK inhibitor - U0126 is present (Additional file 2,
Fig. S2).
Since MCPIP plays a crucial role in the regulation of
inflammation we decided to confirm the involvement of
ERK pathway in the regulation of IL-1b stimulated
ZC3H12A expression in human monocyte-derived
macrophages. In macrophages treated with IL-1b the
level of MCPIP mRNA was elevated and this effect was
partially blocked by ERK inhibitor - U0126 (Fig. 1C).
These data show that the observed mechanism of ERK-
dependent regulation of ZC3H12A by IL-1b is not
restricted to HepG2 cells.
The ZC3H12A promoter is regulated by the transcription
factor Elk-1
Activation of the ERK pathway leads to phosphorylation
of Elk-1. To test the possible role of this transcription
factor in the control of ZC3H12A expression we carried
out transient transfection assays with increasing
amounts of a repressive Elk-1 construct (Elk-En) or a
constitutively active Elk-1 fusion protein (Elk-VP16) and
a 2038 bp long fragment of human ZC3H12A promoter
(-1050 - +988) - pZC3H12A-luc. Both Elk-En and Elk-
VP16 regulated the activity of pZC3H12A-luc in a dose-
dependent manner, with Elk-VP16 activating and Elk-En
repressing as expected (Additional file 3, Fig. S3). To
find sequences responsible for the observed regulation
we have prepared a set of deletion mutants of the
ZC3H12A promoter-driven luciferase reporter construct.
The shortest sequence which still was responsive to Elk-
1 in a dose-dependent manner turned out to be located
between -76 bp and +60 bp, pS-ZC3H12A-luc (Fig. 2).
Bioinformatic analysis revealed that this 136 bp long
fragment contains a hypothetical ets binding site (CAG-
GAA) and a CArG box - SRF binding site (CCATA-
TAAAGG). These experiments suggest that Elk-1 can
contribute to the regulation of ZC3H12A expression.
The presence of an ets binding site and a CArG box
sequence suggests that the observed effect is direct.
The sequence of the CArG box present in the
ZC3H12A promoter differs form the canonical one (7
instead of 6 A-T in the centre). We therefore tested
whether SRF can bind to this sequence in vitro using a
gel retardation assay. As a positive control we used a
fragment of the c-FOS promoter (a known SRF target
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gene). SRF bound to the c-FOS promoter as expected
and binding was also detected on the ZC3H12A promo-
ter fragment containing a wild type CArG box, albeit to
a lower level. In contrast, binding of SRF to the
ZC3H12A promoter was not detected when the CArG
box was mutated (Fig. 3A). These observations demon-
strate that SRF can bind directly to the ZC3H12A pro-
moter, although we were unable to detect Elk-1 binding
in vitro (data not shown).
To demonstrate that endogenous Elk-1 and SRF can
bind to the ZC3H12A promoter in vivo we carried out a
chromatin immunoprecipitation experiment in HepG2
cells. In the presence of Elk-1 antibodies, the ZC3H12A
promoter was precipitated from formaldehyde cross-
linked total cell lysates (Fig. 3B, top panel, lane 2),
whereas control antibodies precipitated background
levels of the ZC3H12A promoter (Fig. 3B and 3C, top
panels, lanes 1 and 3). The promoter of ZC3H12A was
also precipitated in the presence of SRF antibodies (Fig.
3C, top panel, lane 2). IL-1b stimulation had no effect
on the association of either Elk-1 or SRF with the
ZC3H12A promoter (Fig. 3B and 3C, top panel, lane 4).
Both Elk-1 and SRF were also detected as constitutively
associated with the promoter of the well characterized
target gene, an EGR-1 (Fig. 3B and 3C, bottom panels
lanes 2 and 4). These observations demonstrate that
endogenous Elk-1 and SRF bind to the ZC3H12A pro-
moter in vivo, thereby demonstrating that the regulatory
effects of Elk-1 and SRF on ZC3H12A expression are
likely direct.
Stimulation of HepG2 cells by IL-1b leads to
phosphorylation of Elk-1
Phosphorylation of Elk-1 is crucial for its activity. To
confirm that stimulation by IL-1b induces the phosphor-
ylation of Elk-1 through MAPK pathway we performed
western blot analysis using an antibody against
Figure 1 Regulation of expression of human MCPIP. A, control MOCK cells and B, mIB cells with disrupted activation of NFB were treated
with IL-1b (15 ng/ml) and PMA (100 nM). To some experimental groups U0126 (10 μM) was added 30 min prior IL-1b stimulation (lanes 5-8 (A
and B)). RNA was isolated after 2 h and subjected to northern blot analysis using MCPIP cDNA (top panel) or GAPDH cDNA (middle panel) as
probes. Bottom panel - activation of ERK in MOCK and mIkB cells by IL-1b or its inhibition by U0126 was checked by western blot analysis. Cells
were stimulated by IL-1b (15 ng/ml) for 30 min (line 2 and 4). To some experimental groups U0126 (10 μM) was added 30 min prior IL-1b
stimulation (lanes 3-4). Line 1 - lysate from control cells. C, human macrophages were treated with IL-1b (15 ng/ml) with or without U0126 (10
μM, 30 min prior IL-1b stimulation). Changes in ZC3H12A expression were measured by Real Time PCR. The results are means ± SD of three
independent experiments.
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phosphorylated Elk-1. IL-1b induced phosphorylation of
Elk-1 after 5-15 min of stimulation and this modifica-
tion was blocked when the ERK pathway inhibitor -
U0126 was present (Fig. 4A). Therefore in HepG2 cells
stimulation by IL-1b causes phosphorylation of Elk-1
through activation of ERK.
Elk-1 is bound to the promoters of genes independently
of its activation by the MAPK pathway [13,9]. The crucial
factor which changes the state of the Elk-1 on the pro-
moters and induces events leading to activation of the
genes regulated by this transcription factor is phosphory-
lation carried out by ERK, JNK or p38. To test whether
active, phosphorylated forms of Elk-1 could be detected
on the ZC3H12A promoter after IL-1b stimulation, we
performed chromatin immunoprecipitation using anti-
phospho-Elk-1 (P-Ser383) antibody. Phosphorylated Elk-1
could be detected on the ZC3H12A promoter after 15
min treatment with IL-1b (Fig. 4B).
Taken together, these results demonstrate that IL-1b
treatment leads to the increase of Elk-1 phosphorylation
in an ERK pathway-dependent manner and the active
phosphorylated form can be found associated with the
ZC3H12A promoter.
The ZC3H12A promoter is regulated by IL-1b via the ERK
MAPK pathway
To verify the importance of the cloned 136 bp long pro-
moter in the regulation of ZC3H12A expression by IL-
1b we have examined its activation by this proinflamma-
tory cytokine. The 136 bp long promoter was activated
by IL-1b and this activation was blocked by the ERK
pathway inhibitor - U0126 (Fig. 5). Also PMA activated
this promoter and the combination of both factors had
an even greater effect (Fig. 5). These data are broadly in
agreement with the data obtained by northern blot ana-
lysis (Fig. 1A and 1B). In all cases the ERK inhibitor
strongly reduced the observed activation. These results
confirm the involvement of the ERK pathway in the reg-
ulation of ZC3H12A expression by IL-1b and demon-
strate the importance of the 136 bp long promoter
sequence in this regulation.
Functional analysis of ets binding site and CArG box in
the ZC3H12A promoter
The sequence from the human ZC3H12A promoter
located between -76 bp and +60 bp contains an ets
binding site and CArG box, sequences which hypotheti-
cally can bind Elk-1 and its partner SRF. To evaluate
the contribution of these sequences to the observed reg-
ulation by Elk-1 and SRF we introduced point mutations
that abolished binding of Elk-1 or SRF to these ele-
ments. We first assessed the response of this mutant
promoter to activation by IL-1b. The responsiveness of
the mutant ZC3H12A promoter to IL-1b was strongly
reduced in comparison to a reporter construct contain-
ing the wild-type promoter sequence (Fig. 6A). However,
the activation of the 136 bp promoter sequence, without
a functional ets binding site and functional CArG box,
by IL-1b was not completely blocked because this frag-
ment still contains two NFB binding sites [Skalniak
unpublished]. This data confirm the importance of the
ets binding site and the CArG box in the regulation of
ZC3H12A expression by IL-1b.
To confirm that the mutant promoter was unrespon-
sive to Elk-1, we examined its activation by the potent
Elk-VP16 fusion protein. In comparison to the wild-type
promoter, the reporter construct containing the mutated
ets binding site and the mutated CArG box was not
responsive to Elk-VP16 (Fig. 6B). Mutation of either the
Elk-1 or the SRF binding sites was sufficient to abolish
activation of the promoter by Elk-VP16 (Fig. 6C). This is
consistent with a requirement for SRF to recruit Elk-1.
Figure 2 Regulation of activation of 136 bp length ZC3H12A
promoter fragment. Luciferase activity was measured to examine
the regulation of activation of 136 bp length ZC3H12A promoter
fragment. HepG2 cells transiently transfected with the luciferase
construct containing the fragment of human ZC3H12A promoter
located between -76 bp and +60 bp. Increasing amounts of pElk-En
(20, 50, 100, 200 ng - lanes 2, 3, 4, 5) or Elk-VP16 (20, 50, 100, 200
ng - lanes 6, 7, 8, 9) were co-transfected to the cells. Lane 1 -
control cells without Elk-En or Elk-VP16. Luciferase activity was
measured 24 h after transfection. Statistical significance was
determined using the Student’s test. *P < 0.05, **P < 0.001.
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Together these data therefore demonstrate the impor-
tance of the ets and SRF binding elements in promoter
responsiveness to Elk-1 activity and activation by IL-1b.
Discussion
Elk-1 is a known regulator of the expression of immedi-
ate-early genes, mainly transcription factors, which in
turn regulate the expression of other genes coding for
proteins engaged in the response of the cell to the chan-
ging environment. Thus, activation of Elk-1 is at the top
of events leading to a global changes in the cell beha-
vior. Here we have identified a new Elk-1 target gene,
ZC3H12A, that encodes a recently discovered protein
whose biological function is the control of mRNA turn-
over. Transcripts for IL-6, IL-12p40 and the calcitonin
receptor are found to be regulated by MCPIP [1] and
we have recently found that MCPIP regulates the turn-
over of IL-1b mRNA [2]. The latter finding is intriguing
and suggests the existence of an autoregulatory loop as
here we show the importance of IL-1b in controlling the
expression of ZC3H12A. The results indicate the exis-
tence of a negative regulatory loop, contributing to shut
down of IL-1b synthesis.
The mechanisms controlling the regulation of the
expression of ZC3H12A are not known. ZC3H12A is an
immediate-early gene regulated by the proinflammatory
cytokine IL-1b [2] through the activation of NFB (Fig.
1; [10]). However in the mIB cells with a defect in the
activation of NFB, IL-1b is still able to elevate MCPIP
mRNA level (Fig. 1B). Our results suggest that apart
from the NFB activation pathway, the MAPK pathway
is also engaged in the regulation of ZC3H12A expres-
sion. ZC3H12A promoter deletion constructs allowed us
to find a minimal promoter 136 bp fragment which is
still responsive to MAPK pathway activation. Bioinfor-
matic analysis revealed that this region contains a
hypothetical Elk-1 binding site (ets-binding site) - CAG-
GAA. The sequences recognized by Elk-1 differ amongst
Figure 3 SRF and Elk-1 bind to the ZC3H12A promoter. A, Gel retardation assay with a fragment of ZC3H12A promoter (-95 - +67) containing
the WT sequence or a mutated CArG box (ZC3H12A-mut) or a fragment of c-Fos promoter. The DNA was incubated with coreSRF. B and C,
Chromatin immunoprecipitation of the transcription factors Elk-1 (B) and SRF (C) bound to the ZC3H12A promoter. HepG2 cells were incubated
in 0.5% FCS medium for 12 hrs and then stimulated for 30 min with IL-1b. The antibodies anti-Elk-1 (B) or anti-SRF (C) were used to
immunoprecipitate sonicated chromatin. As a negative control non-specific IgG were employed. Eluted DNA served as a template in PCR analysis
with oligonucleotides specific for ZC3H12A promoter (top panel B and C) or EGR promoter (bottom panel B and C). 1% of input DNA is shown
in lines 5 and 6. The panels show the inverted images of ethidium bromide-stained gels.
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binding sites. The core GGA is always included in the
ets-binding site but the flanking residues may differ.
The most frequent motif is CCGGAA (in promoters of
the Elk-1-regulated genes such as EGR-1, TR3, Pip92,
MCL-1, SRF) [14,15,13]. However, other known Elk-1
target genes like c-FOS possess the sequence CAGGAT,
whereas another one nur77, contains the GAGGAA
motif [16,14]. Elk-1 as a member of the TCF subfamily
can form ternary complexes on target promoters
together with serum response factor (SRF). Indeed,
there is a CArG box, an SRF binding site, in the 136 bp
fragment of ZC3H12A promoter (CCATATAAAGG).
The consensus CArG box sequence is CC(A/T)6GG
although there are exceptions from this rule. For exam-
ple TR3 has CCTGTATGG and nur77 CTATTTATAG
[14]. The lack of one of the G:C base pairs flanking the
central hexameric A/T rich region probably explains the
lower level of binding we observe in comparison to the
Figure 4 IL-1b causes ERK-dependent phosphorylation of Elk-1 on ZC3H12A promoter. A, Activation of Elk-1 after IL-1b stimulation. HepG2
cells were stimulated by IL-1b (15 ng/ml) for 5, 10 and 15 min and the phosphorylation of Elk-1 was analyzed by western blot analysis. To some
experimental groups U0126 (10 μM) was added 30 min prior IL-1b stimulation (lanes 5-8). Asterisks indicate unspecific bands. B, Chromatin
immunoprecipitation of the phosphorylated Elk-1 bound to the ZC3H12A promoter. HepG2 cells were incubated in 0.5% FCS medium for 12 hrs
and then stimulated for 15, 30 or 90 min with IL-1b. The antibodies anti-P-Elk were used to immunoprecipitate sonicated chromatin. As a
negative control non-specific IgG were employed. Eluted DNA served as a template in PCR analysis with oligonucleotides specific for ZC3H12A
promoter. 1% of input DNA is shown in lines 9-12. The panels show the inverted images of ethidium bromide-stained gels.
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c-FOS promoter, which contains a canonical binding
motif. However, the relative in vitro binding affinity and
match to the consensus does not necessarily correlate
with in vivo occupancy level as demonstrated by ChIP-
chip analysis [17]. Indeed, we detect SRF binding by
ChIP analysis to this promoter. Simultaneous mutation
of both, the ets-binding site and CArG box completely
blocked activation of 136 bp promoter fragment by
either a constitutively active form of Elk-1 (Elk-VP16) or
by PMA treatment. Activation of this fragment by IL-1b
is strongly reduced although not blocked completely
and this remaining responsiveness to IL-1b is probably
due to two hypothetical NFkB binding sites still present
in the 136 bp promoter fragment [Skalniak unpub-
lished]. All these results suggest involvement of the ERK
MAPK pathway leading to activation of Elk-1 in the reg-
ulation of ZC3H12A expression by IL-1b. Indeed, we
demonstrate binding of Elk-1 to ZC3H12A promoter in
vivo through ChIP analysis. Elk-1 binding to the
ZC3H12A promoter is detectable in the presence and
absence of stimulation with IL-1b, thus, changes in pro-
moter occupancy does not appear to be the activation
mechanism. Binding of Elk-1 to ets-binding sites of
other genes in unstimulated cells was reported earlier
[13]. Such binding is not sufficient for activation of
genes regulated by Elk-1 since Elk-1 in unstimulated
cells is sumoylated and interacts with HDAC-2. This
modification keeps Elk-1 in a repressive form [6]. Our
data show that IL-1b induces phosphorylation of Elk-1
and phosphorylated Elk-1 is present on the ZC3H12A
promoter (Fig. 4). The Elk-1 partner protein, SRF, is
also bound to the ZC3H12A promoter and this binding
is also not increased upon IL-1b stimulation indicating
again that transcription factor recruitment does not
appear to be a key regulatory event (Fig. 3C). This
seems to be a more general mechanism since the occu-
pancy of EGR-1 promoter by SRF and Elk-1 is also inde-
pendent of IL-1b stimulation. It has to be noticed that
apart from the NFB activation pathway and the ERK
pathway another yet unknown pathway contributes to
the regulation of ZC3H12A expression. In mIB cells
treated with the ERK inhibitor the activation of
ZC3H12A expression by IL-1b is still observed (Fig. 1).
Our preliminary data indicate that p38 and JNK could
participate in this process.
Conclusions
In summary, our results demonstrate a role of Elk-1 in
the regulation of the expression of MCPIP - an RNAse
important in inflammation. Until now, Elk-1 was gener-
ally thought to be involved in regulation of proliferation
and apoptosis [18]. Our discovery has therefore poten-
tially broadened the role of Elk-1 as factor which also
controls the course of inflammation.
Our results reveal also existence of negative regulatory
loop controlling the synthesis of IL-1b. IL-1b regulates
the expression of MCPIP, an RNase which contributes
to the turn-over of IL-1b mRNA (Fig. 7).
Methods
Cell culture
HepG2 cells (ATCC), MOCK cells and mIB cells were
cultured at 37°C and 5%CO2 in Dulbecco Modified
Eagle Medium (DMEM) with 1000 mg/l D-glucose
(Gibco/BRL) supplemented with 10% foetal bovine
Figure 5 Regulation of activation of 136 bp length ZC3H12A
promoter fragment. Luciferase activity was measured to examine
the regulation of activation of 136 bp length ZC3H12A promoter
fragment. HepG2 cells were transiently transfected with the
luciferase construct containing the fragment of human ZC3H12A
promoter located between -76 bp and +60 bp. 24 hrs after
transfection cells were stimulated with IL-1b or/and PMA for 3 hrs.
An inhibitor U0126 was added to cells 30 min prior stimulation.
Statistical significance was determined using the Student’s test. *P <
0.05, **P < 0.001. Bottom panel - activation of ERK by IL-1b or its
inhibition by U0126 was checked by western blot analysis Cells
were stimulated by IL-1b (15 ng/ml) for 30 min (line 2 and 4). To
some experimental groups U0126 (10 μM) was added 30 min prior
IL-1b stimulation (lanes 3-4). Line 1 - lysate from control cells.
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serum (FBS). HepG2 cells stably transfected with retro-
viral vector pCFG5-IEG2, containing a nondegradable
mutant form of IBa (mIB cells), and cells with an
empty vector (control, MOCK cells) were used for
determination of significance of NFB signalling path-
way in IL-1-dependednt activation of ZC3H12A. The
transfected cells were kindly provided by Professor Ste-
phan Ludwig (Heinrich-Heine University, Duesseldorf,
Germany [19].
Human monocyte-derived macrophages (hMDMs)
were separated from fractions of peripheral blood
mononuclear cells (PBMCs) obtained from the blood of
healthy donors using a lymphocyte separation medium
(LSM; PAA) density gradient [20]. Briefly, isolated
PBMCs were seeded 2 × 107 /well in 6-well plates (Sar-
stedt) in RPMI1640 (PAA) containing 2 mM L-gluta-
mine, 50 μg ml-1 gentamycin (Sigma), and 10% heat-
inactivated autologous human plasma. After 24 h non-
adherent cells were removed and remaining adherent
monocytes were cultured for 7 days with fresh medium
added every second day. The amount of serum was
diminished to 0,5% 16 h before stimulation. hMDMs
were stimulated with IL-1b (15ng/ml) for 2 h. When
necessary an inhibitor U0126 was added 0,5 h before
the cytokine stimulation.
Cytokine and cell stimulation
Cells were stimulated with 15 ng/ml IL-1b (R&D), 100
nM PMA (Calbiochem). When applied, the inhibitor of
MEK1/2, U0126 (10 μM) (Calbiochem) was added to
the medium at 30 min prior stimulation.
RNA preparation, Northern blot analysis and Real Time
PCR
Total RNA was prepared using Chomczynski method
with modifications as described before [21]. Ten micro-
gram samples of RNA were subjected to formaldehyde
gel electrophoresis and northern blot analysis was car-
ried out as described previously [18]. For RT-PCR the
first strand of cDNA was synthesized from 2 μg of total
RNA using MMLV reverse transcriptase (Promega) and
oligo(dT) primer. Real time PCR was performed using
the SYBR Green PCR Master Mix (DyNAmo™ HS SYBR
Green qPCR (Finnzyme). Each sample was normalized
to reference gene (elongation factor 2) and the relative
level of transcripts was quantified by ΔΔCT method.
Figure 6 Mutation of both ets-binding site and CArG box abolished the activation of 136 bp length ZC3H12A promoter fragment.
Luciferase activity was measured to examine the regulation of 136 bp length ZC3H12A promoter fragment. HepG2 cells were transiently
transfected with the luciferase construct containing the fragment of human ZC3H12A promoter located between -76 bp and +60 bp. Black bars -
wild type promoter, striped bars - promoter with the mutation in both ets-binding site and in CArG box. A, 24 h after transfection cells were
stimulated with IL-1b and PMA for 3 hrs. B, Cells were co-transfected with increasing amounts of Elk-VP16 (20, 50 ng). Luciferase activity was
measured 24 h after transfection. C, Influence of mutation of ets-binding site or CArG box on the activation of 136 bp by Elk-1. Black bars
represent wild type promoter, dotted bars represent promoter with the mutation in ets-binding site, light bars represent promoter with the
mutation in CArG box. Cells were co-transfected with increasing amounts of Elk-VP16 (10, 20, 50 ng). Luciferase activity was measured 24 h after
transfection. Statistical significance was determined using the Student’s test. *P < 0.05, **P < 0.001.
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Nuclear extract preparation and EMSA test
HepG2, MOCK cells and mIB cells were stimulated
with IL-1b for 90 min Nuclear extracts from stimulated
and unstimulated cells were prepared as described pre-
viously [22]. For NFB binding assay double-stranded
probes were labeled by filling in 5’ protruding ends with
Klenow enzyme using [a-32P]dCTP (3000 Ci/mmol).
After purification with Qiagen system, the probes
(10000-20000 cpm of 32P-labelled NFB-binding oligo-
nucleotide: 5’agcttcagaggggactttccgagagg) were incubated
with 10 μg of nuclear extracts for 30 min at room
temperature. For SRF binding gel retardation assay was
carried out with 32P-labeled 162-base pair fragment of
human ZC3H12A promoter generated by PCR on tem-
plates pS-ZC3H12A-luc (WT) and pS-ZC3H12A-luc
(mCArG) (primers: GCCGCGACGCGAGGAGCGG and
GTCCTGGGGGTAAGGACGGCG) as described pre-
viously [13]. CoreSRF was produced as a glutathione S-
transferase-tagged protein in bacteria.
Plasmid constructs
pEF1/Myc-His/lacZ is a control vector containing the
gene for b-galactosidase (Invitrogen). pElk-VP16 is a
Figure 7 Schematic diagram of regulation of the ZC3H12A promoter by IL-1b. IL-1RI - type I IL-1 receptor, IL-1R AcP - IL-1 receptor
accessory protein. The main sequences responsible for binding of NFB are located within the second intron of ZC3H12A promoter [10].
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Rous sarcoma virus promoter-driven vector encoding
full-length wild type Elk-1 fused to residue 410-490 of
the VP16 C-terminal sequence [22,13]. pElk-En is a
CMV promoter-driven vector encoding full-length wild
type Elk-1 fused to residue 2-298 of the engrailed
repressor domain [13]. pZC3H12A-luc, containing 2038
bp long fragment of human ZC3H12A promoter (-1050
- +988), was generated by PCR cloning of this fragment
to the pGL4 reporter vector (Promega). The 2038 bp
fragment of human ZC3H12A promoter was obtained
by two step PCR, using total DNA isolated from HepG2
cells. The first round PCR was carried out with the pri-
mer forward: GTGGCTCTGTCCTCCAGCGTGT and
reverse: CTGGCTTCCAGGACAGGCTTC. Then the
second round of PCR was performed with nested pri-
mers: forward with restriction site for XhoI:
CCGCTCGAGCTCCAGCGTGTGGGCTCTGTG and
reverse with restriction site for HindIII and mutated
initiation of translation codon ATG: CCCAAGCTTGC-
CACTGATAGCTCAGACTCCTG The introduced
restriction sites were used during cloning of PCR pro-
duct into the pGL4 vector. pS-ZC3H12A-luc, containing
136 bp long fragment of human ZC3H12A promoter
(-76 - + 60) was generated using PCR product obtained
with the following primers: forward with XhoI restric-
tion site: CTCGAGAGCAGGAAGGGGCGAGGCAGCC
and reverse with HindIII restriction site:
GGGAAGCTTCGGCGGCGCCTTTATATGGGGCG
and using pZC3H12A-luc as a template. All genetic con-
structs were sequenced before transfection experiments.
The constructs containing mutations in ets-binding site
or CArG box were generated using QuickChange Site-
Directed Mutagenesis kit (Stratagene) according to the
manufacturer’s procedure. The sequence GCAGGAA
was changed to GaAttcA, the sequence CCATA-
TAAAGGC was changed to CCATATgaattc, both muta-
tions generated EcoRI restriction site.
Reporter gene assay
Transient transfection experiments were carried out
using Lipofectamine 2000 reagent (Invitrogen) in 12-
weel plate. Total amount of 1.6 μg of DNA per each
well was used, including 0.4 μg of pZC3H12A-luc or
pS-ZC3H12A-luc and 10 ng of pEF1/Myc-His/lacZ. For
some experiments indicated amounts of pElk-En or Elk-
VP16 were used. The amount of DNA per well was
equalized using mock DNA (pcDNA3). Luciferase assays
were carried out using the dual light reporter gene assay
system (Tropix) according to the manufacturer’s proce-
dure. b-galactosidase activity was measured to normal-
ized the efficiency of transfection. All experiments were
repeated at least three times in duplicates.
Western blot
Western blot was carried out using Immobilon Western
chemiluminescent HRP substrate (Millipore) and
antibodies anti-phospho-Elk-1, anti-phospho-ERK (Santa
Cruz) and anti-GAPDH (Abcam).
Chromatin immunoprecipitation
Chromatin immunoprecipitations were carried out as
described previously [16], using anti-Elk-1, anti-P-Elk
(P-Ser383) and anti-SRF (Santa Cruz) or nonspecific
IgG (Upstate) antibodies. Promoter-specific primers
were used to amplify the DNA by PCR: human
ZC3H12A promoter: forward: CAGGTGCGTGTACCT-
GATTC and rewerse: CGAGTCCTGGGGGTAAGG,
and human egr-1 promoter: forward: TGCAGGATG-
GAGGTGCC and reverse: AGTTCTGCGCGCTGG-
GATCTC. Where indicated cells were stimulated 30
min by IL-1b (15 ng/ml).
Additional file 1: Fig. S1. Activation of NFB in HepG2, MOCK and
mIB cells. Nuclear extract was isolated from HepG2 cells, MOCK cells
and mIB cells. Where indicated cells were stimulated with IL-1b (15 ng/
ml). By gel retardation assay NFB activation was measured.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2199-11-
14-S1.PPT ]
Additional file 2: Fig. S2. Activation of ERK by IL-1b in HepG2 cells.
HepG2 cells were stimulated by IL-1b (15 ng/ml) for 15 and 30 min and
the phosphorylation of ERK1/2 was analyzed by western blot analysis. To
some experimental groups U0126 (10 μM) was added 30 min prior IL-1b
stimulation (lanes 4-6)
Click here for file.
[ http://www.biomedcentral.com/content/supplementary/1471-2199-11-
14-S2.PPT ]
Additional file 3: Fig. S3. Regulation of 2038 bp length ZC3H12A
promoter fragment by Elk-1. HepG2 cells were transiently transfected
with the luciferase construct containing fragment of human ZC3H12A
promoter located between -1050 and +988 and increasing amounts of
pElk-En (20, 50, 100, 200 ng - lanes 2, 3, 4, 5) or Elk-VP16 (20, 50, 100, 200
ng - lanes 6, 7, 8, 9). Lane 1 - control cells without Elk-En or Elk-VP16.
Luciferase activity was measured 24 h after transfection. Statistical
significance was determined using the Student’s test. *P < 0.05, **P <
0.001.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2199-11-
14-S3.PPT ]
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